Ardelyx Inc
Company Profile
Business description
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Contact
400 Fifth Avenue
Suite 210
WalthamMA02451
USAT: +1 510 745-1700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
395
Stocks News & Analysis
stocks
Oracle shares are up 87% in 2025. Is it a buy?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,067.90 | 38.40 | -0.42% |
| CAC 40 | 7,872.02 | 41.91 | 0.54% |
| DAX 40 | 23,611.33 | 84.28 | 0.36% |
| Dow JONES (US) | 46,292.78 | 88.76 | -0.19% |
| FTSE 100 | 9,223.32 | 3.36 | -0.04% |
| HKSE | 26,073.69 | 85.43 | -0.33% |
| NASDAQ | 22,573.47 | 215.50 | -0.95% |
| Nikkei 225 | 45,309.43 | 184.23 | -0.40% |
| NZX 50 Index | 13,124.14 | 12.40 | -0.09% |
| S&P 500 | 6,656.92 | 36.83 | -0.55% |
| S&P/ASX 200 | 8,779.50 | 35.50 | -0.40% |
| SSE Composite Index | 3,821.47 | 0.37 | -0.01% |